Login to Your Account



Allicense 2011

New, Evolving Platforms Keep MAbs at Forefront in Licensing

By Jennifer Boggs


Thursday, May 5, 2011
SAN FRANCISCO – It's impossible to imagine the biotech space without monoclonal antibodies. A recent report by Deloitte Recap LLC showed that about a third of marketed mAbs in 2009 hit blockbuster status, and experts are predicting that in a few years, the top-selling drugs will be Roche AG's Avastin (bevacizumab) and Abbott's Humira (adalimumab).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription